

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Stephen P. MASSIA *et al.*

Serial No.: 10/716,293

Filed: November 17, 2003

For: THERAPEUTIC BIOCONJUGATES

Group Art Unit: 1654

Examiner: Niebauer, Ronald T.

Atty. Dkt. No.: AZTE:015US

Confirmation No.: 8809

CERTIFICATE OF ELECTRONIC TRANSMISSION  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below.

November 19, 2007

Date

Mark E. Wilson

**AMENDMENT AND RESPONSE TO OFFICE COMMUNICATION DATED  
OCTOBER 17, 2007, REGARDING NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 23313-1450

Commissioner:

This paper is submitted in response to the Office Communication dated October 17, 2007, setting forth a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, for which the date for response is November 19, 2007 (November 17, 2007 falls on a Saturday).

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Account L.L.P. No.: 50-1212/AZTE:015US.

**An Amendment to the specification** begins on page 3 of this paper.

**A Response** begins on page 5 of this paper.

Reconsideration of the application in view of the amendments and remarks contained herein is respectfully requested.